NEW YORK, Oct. 7 (GenomeWeb News) - Inproteo (formerly known as the Indiana Proteomics Consortium) said today that it has licensed US Patent No. 4,569,794 -- which protects a fusion protein purification technique known commonly as "His Tag" -- to Biogen.
"This license allows Biogen to have complete use of the technology for their research, development and commercialization activities," said Dr. John Hurrell, president of Inproteo.
Eli Lilly and Company, the original assignee on the patent, granted a license to Inproteo with exclusive right to issue sub-licenses, Inproteo said.
Inproteo said that a number of life science and biopharmaceutical companies have already concluded a licensing agreement and that the consortium is "holding discussions with numerous other companies, research institutes, and universities to license the patent for research and commercial use."
Inproteo was founded in 2002 as a collaboration between Indiana University, Purdue University, and Eli Lilly and Company.